Advancing T1D Science: New TRI Publications

Researchers at the AdventHealth Translational Research Institute continue to drive meaningful progress in Type 1 diabetes—work that is being recognized not just in Central Florida, but throughout the national and global research community. This year, our teams have contributed to clinical trials, translational studies, and real-world investigations that are deepening our understanding of T1D and its complications. Our efforts are helping refine treatments, improve patient outcomes, and guide the next generation of therapies and clinical care.

Below is a look at several recent publications from TRI investigators—each one expanding what we know and bringing us closer to better, safer, and more personalized care for people living with Type 1 diabetes.

FINE-ONE: New Hope for CKD & T1D

One of the most significant studies this year is FINE-ONE, a landmark study exploring a potential new therapy for adults with T1D and chronic kidney disease—an area where treatment options remain limited. In this Q&A with Tina Thethi, MD, MPH, we unpack what the findings mean for patients, why this study matters, and how it aligns with TRI’s mission to advance meaningful, real-world care.
👉 Read the Q&A: https://www.adventhealth.com/foundation/adventhealth-foundation-central-florida/blog/fine-one-new-hope-ckd-and-type-1-diabetes

Continuous Glucose Monitoring (CGM) & Hypoglycemia Awareness in Older Adults

A fresh look at data from the WISDM Study asked an important question: Can CGM help older adults “feel” their low blood sugars again? Many people with long-standing T1D lose the early warning signs of hypoglycemia, increasing the risk of dangerous lows. This post-hoc analysis found encouraging signs that regular CGM use may help restore some of those warning symptoms, while also reducing severe hypoglycemia events. It’s an early but meaningful insight into how technology can support safety, confidence, and independence in older adults.
🔗 https://pubmed.ncbi.nlm.nih.gov/40902121/

How Different Diets Impact T1D

A new meta-analysis tackles a question many people living with T1D ask: Which eating patterns truly help with weight management and stable blood sugar? By reviewing multiple clinical trials, researchers identified several evidence-based dietary approaches—not one “perfect diet,” but a set of sustainable patterns shown to improve daily glucose control and long-term health. This study helps cut through mixed messages and gives people clearer, research-backed guidance on how to eat well with Type 1 diabetes

🔗 https://pubmed.ncbi.nlm.nih.gov/40795275/

Making Automated Insulin Delivery Smarter & Safer

As automated insulin delivery (AID) systems become more common, understanding their strengths—and their limitations—has never been more important. This expert consensus paper outlines where AID technology excels today and where critical research gaps remain, from algorithm improvement to personalization and long-term safety. The roadmap it provides highlights opportunities that could make future systems more responsive, reliable, and tailored to the unique needs of each individual with T1D.
🔗 https://pubmed.ncbi.nlm.nih.gov/40590746/

Boosting the Body’s Low-Blood-Sugar Defense

Another recent study explored a promising idea: Could a GPR119 agonist strengthen the glucagon response during hypoglycemia? Because many people with T1D lose their natural defenses against severe lows, improving this response could be a major step forward. This randomized, double-masked crossover trial offers early evidence that activating the GPR119 pathway may help restore that protective mechanism, opening the door to potential new therapies aimed at reducing severe hypoglycemia risk.
🔗 https://pubmed.ncbi.nlm.nih.gov/40173094/